Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma
Background. Bone marrow infiltration of lymphoma cells is a candidate risk factor for infusion-related reactions (IRRs) in patients with CD20-positive B-cell non-Hodgkin lymphoma (B-NHL). However, despite with the lack of sufficient data, the effect of bone marrow infiltration of B-NHL cells on the...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2022/3688727 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565578898866176 |
|---|---|
| author | Shinya Ohata Kei Takenaka Daisuke Sugiyama Takeshi Sugimoto |
| author_facet | Shinya Ohata Kei Takenaka Daisuke Sugiyama Takeshi Sugimoto |
| author_sort | Shinya Ohata |
| collection | DOAJ |
| description | Background. Bone marrow infiltration of lymphoma cells is a candidate risk factor for infusion-related reactions (IRRs) in patients with CD20-positive B-cell non-Hodgkin lymphoma (B-NHL). However, despite with the lack of sufficient data, the effect of bone marrow infiltration of B-NHL cells on the incidence rate of grade 2 or higher IRRs with the administration of rituximab has been retrospectively studied in this paper. Methods. Patients with CD20-positive B-NHL who received the rituximab induction therapy for the first time were enrolled in this study. To evaluate the bone marrow infiltration of B-NHL cells, May–Giemsa stain of bone marrow films and flow cytometry examination of bone marrow aspiration samples were performed. IRR grade was determined using the IRR criteria in the Common Terminology Criteria for Adverse Events version 4.0. Results. A total of 127 patients were eligible for this study. Grade 2 or higher IRRs were observed in 43 (34%) patients. In univariate analysis, use of glucocorticoid before rituximab infusion was a strong risk-avoiding factor for grade 2 or higher IRRs. Advanced stage of disease (Ann Arbor: stages III and IV) or bone marrow infiltration of B-NHL cells revealed the risk factors, regardless of glucocorticoid premedication. Using multivariate analysis, bone marrow infiltration was found to be an independent risk factor for patients without prior glucocorticoid use. Conclusion. Bone marrow infiltration of B-NHL cells is a risk factor for grade 2 or higher IRRs at the first rituximab induction therapy without glucocorticoid premedication. |
| format | Article |
| id | doaj-art-413e6bc178c24001ad62c64c871d0b21 |
| institution | Kabale University |
| issn | 1687-9112 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-413e6bc178c24001ad62c64c871d0b212025-02-03T01:07:10ZengWileyAdvances in Hematology1687-91122022-01-01202210.1155/2022/3688727Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin LymphomaShinya Ohata0Kei Takenaka1Daisuke Sugiyama2Takeshi Sugimoto3Department of Hematology and OncologyDepartment of Hematology and OncologyFaculty of Nursing and Medical CareDepartment of Hematology and OncologyBackground. Bone marrow infiltration of lymphoma cells is a candidate risk factor for infusion-related reactions (IRRs) in patients with CD20-positive B-cell non-Hodgkin lymphoma (B-NHL). However, despite with the lack of sufficient data, the effect of bone marrow infiltration of B-NHL cells on the incidence rate of grade 2 or higher IRRs with the administration of rituximab has been retrospectively studied in this paper. Methods. Patients with CD20-positive B-NHL who received the rituximab induction therapy for the first time were enrolled in this study. To evaluate the bone marrow infiltration of B-NHL cells, May–Giemsa stain of bone marrow films and flow cytometry examination of bone marrow aspiration samples were performed. IRR grade was determined using the IRR criteria in the Common Terminology Criteria for Adverse Events version 4.0. Results. A total of 127 patients were eligible for this study. Grade 2 or higher IRRs were observed in 43 (34%) patients. In univariate analysis, use of glucocorticoid before rituximab infusion was a strong risk-avoiding factor for grade 2 or higher IRRs. Advanced stage of disease (Ann Arbor: stages III and IV) or bone marrow infiltration of B-NHL cells revealed the risk factors, regardless of glucocorticoid premedication. Using multivariate analysis, bone marrow infiltration was found to be an independent risk factor for patients without prior glucocorticoid use. Conclusion. Bone marrow infiltration of B-NHL cells is a risk factor for grade 2 or higher IRRs at the first rituximab induction therapy without glucocorticoid premedication.http://dx.doi.org/10.1155/2022/3688727 |
| spellingShingle | Shinya Ohata Kei Takenaka Daisuke Sugiyama Takeshi Sugimoto Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma Advances in Hematology |
| title | Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma |
| title_full | Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma |
| title_fullStr | Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma |
| title_full_unstemmed | Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma |
| title_short | Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma |
| title_sort | bone marrow infiltration is a distinctive risk factor for rituximab infusion related reactions in cd20 positive b cell non hodgkin lymphoma |
| url | http://dx.doi.org/10.1155/2022/3688727 |
| work_keys_str_mv | AT shinyaohata bonemarrowinfiltrationisadistinctiveriskfactorforrituximabinfusionrelatedreactionsincd20positivebcellnonhodgkinlymphoma AT keitakenaka bonemarrowinfiltrationisadistinctiveriskfactorforrituximabinfusionrelatedreactionsincd20positivebcellnonhodgkinlymphoma AT daisukesugiyama bonemarrowinfiltrationisadistinctiveriskfactorforrituximabinfusionrelatedreactionsincd20positivebcellnonhodgkinlymphoma AT takeshisugimoto bonemarrowinfiltrationisadistinctiveriskfactorforrituximabinfusionrelatedreactionsincd20positivebcellnonhodgkinlymphoma |